Table 2.
Outcome parameters
| Variables | BuFlu N = 17 (%) | FBM N = 22 (%) | FluMel N = 22 (%) | p value |
|---|---|---|---|---|
| Median days to neutrophil engraftment (range) | 17 (12–36) | 16 (13–22) | 16 (10–52) | 0.29a |
| Median days to platelet engraftment (range) | 22 (8–56) | 22 (12–55) | 24 (18–98) | 0.45a |
| Day +30 (%) chimerism: | <0.001b | |||
| CD3 100 % donor | 2 (18) | 19 (86) | 8 (89) | <0.012 |
| CD33 100 % donor | 7(64) | 22 (100) | 16 (94) | |
| Day +100 (%) chimerism: | <0.001b | |||
| CD3 100 % donor | 1 (11) | 16 (89) | 7 (78) | <0.001b |
| CD33 100 % donor | 4 (44) | 18 (100) | 9 (90) | |
| Acute GVHD, any grade | 8 (47) | 18 (82) | 17 (77) | 0.04b |
| Acute GVHD, grade 2–4 | 8 (47) | 15 (68) | 15 (68) | 0.31b |
| Acute GVHD, grade 3–4 | 6 (35) | 6 (27) | 10 (46) | 0.45b |
| Chronic GVHD | 6 (35) | 8 (36) | 13 (59) | 0.22B |
| Relapse | 5 (29) | 2 (9) | 3 (14) | 0.21b |
| Dead at time of analysis | 8 (47) | 7 (32) | 10 (46) | 0.55b |
| Non-relapse mortality | 5 (29) | 6 (27) | 9 (41) | 0.32b |
| Poor graft function day +100 | 6 (38) | 5 (25) | 4 (24) | 0.90b |
Percentages calculated taking into account missing data; 1Chi square; 2Kruskal–Wallis BuFlu Busulfan and Fludarabine, FBM Fludarabine BCNU and Melphalan, FluMel Fludarabine and Melphalan, GVHD graft-versus-host disease Bold are the values that are statistically significant
a
Χ2 test
b
Kruskal–Wallis